nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

04.03.2019 | Letter to the Editor

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma

verfasst von: Nicolas Albin, Adrien Monard, Jérémy Lapiere

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Lee A, Sun S, Sandler A, Hoang T (2018) Recent progress in therapeutic antibodies for cancer immunotherapy. Curr Opin Chem Biol 44:56–65CrossRefPubMed

Palmieri DJ, Carlino MS (2018) Immune checkpoint inhibitor toxicity. Curr Oncol Rep 20(9):72CrossRefPubMed

Intlekofer AM, Craig BT (2013) At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 94(1: juillet):2539

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL (2016) Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34(24):292534CrossRef

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356CrossRefPubMedPubMedCentral

The French National Authority for Health (HAS) (2017) Transparency Commission CT15561_OPDIVO_PIC_EI_association_Yervoy_melanome_Avis2_CT15561.pdf. https://www.has-sante.fr/portail/upload/docs/evamed/CT-15561_OPDIVO_PIC_EI_association_Yervoy_melanome_Avis2_CT15561.pdf. [the easiest access to this source is via the URL]

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290CrossRefPubMedPubMedCentral

European Medicines Agency Committe for Medicinal Products for Human Use-London (2018) EMA/CHMP/457661/2018 Opinion of the committee for medicinal products for human use on a type II variation to the terms of the marketing authorisation. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002213/WC500252687.pdf. [the easiest access to this source is via the URL]

Hellman MD, Ciuleanu T, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104CrossRef

10.

Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG (2018) Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25(11):1327–1339CrossRefPubMed

11.

Legifrance (2018) Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l’article L. 162-16-6 du code de la sécurité sociale. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000034183611&categorieLien=id

Titel: The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
verfasst von: Nicolas Albin
Adrien Monard
Jérémy Lapiere
Publikationsdatum: 04.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03804-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Determination of melphalan in human plasma by UPLC–UV method

The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie